1. Home
  2. LEA vs ERAS Comparison

LEA vs ERAS Comparison

Compare LEA & ERAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Lear Corporation

LEA

Lear Corporation

HOLD

Current Price

$137.61

Market Cap

6.3B

ML Signal

HOLD

Logo Erasca Inc.

ERAS

Erasca Inc.

HOLD

Current Price

$10.37

Market Cap

5.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LEA
ERAS
Founded
1917
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Auto Parts:O.E.M.
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
6.3B
5.5B
IPO Year
1994
2021

Fundamental Metrics

Financial Performance
Metric
LEA
ERAS
Price
$137.61
$10.37
Analyst Decision
Buy
Strong Buy
Analyst Count
14
12
Target Price
$132.21
$14.25
AVG Volume (30 Days)
530.0K
9.6M
Earning Date
05-01-2026
05-08-2026
Dividend Yield
2.49%
N/A
EPS Growth
N/A
36.23
EPS
3.34
N/A
Revenue
$23,259,100,000.00
N/A
Revenue This Year
$2.50
N/A
Revenue Next Year
$3.12
N/A
P/E Ratio
$41.74
N/A
Revenue Growth
N/A
N/A
52 Week Low
$86.14
$1.06
52 Week High
$142.84
$24.28

Technical Indicators

Market Signals
Indicator
LEA
ERAS
Relative Strength Index (RSI) 64.69 36.46
Support Level $115.63 $2.07
Resistance Level $142.84 $16.14
Average True Range (ATR) 4.46 1.41
MACD 1.16 -0.70
Stochastic Oscillator 85.48 10.65

Price Performance

Historical Comparison
LEA
ERAS

About LEA Lear Corporation

Lear Corp designs, develops, and manufactures automotive seating and electrical systems and components. The company has two reporting segments Seating and E-Systems. Seating components include frames and mechanisms, covers (leather and woven fabric), seat heating and cooling, foam, and headrests. Automotive electrical distribution and connection systems and electronic systems include wiring harnesses, terminals and connectors, on-board battery chargers, high-voltage battery management systems. The company earns majority of its revenue from the seating segment.

About ERAS Erasca Inc.

Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Its focused RAS/MAPK pathway pipeline comprises modality-agnostic programs aligned with three therapeutic strategies of: targeting key upstream and downstream signaling nodes in the RAS/MAPK pathway; targeting RAS directly; and targeting escape routes that emerge in response to treatment. Its pipeline includes two clinical-stage programs (ERAS-0015, a pan-RAS molecular glue; and ERAS-4001, a pan-KRAS inhibitor), and ERAS-12, a discovery-stage program.

Share on Social Networks: